ClinicalTrials.gg
Active, not recruitingNCT04091126DREAMM 9Updated Nov 9, 2026Results posted

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

A Phase 1 interventional study of Belantamab mafodotin and Bortezomib in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Nov 9, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
11th of 49
118 · median 50
Started
2019
with 4 others
Phase 1
11 of 49
3 open now
Primary completion
2025-06
later than 14 of 34 live
Registered
5th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 11th largest by enrollment, is one of 5 that started in 2019, is one of 11 in phase 1, reaches primary completion later than 14 of the 34 other live ones, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Bortezomib
  • Lenalidomide
  • dexamethasone
  • VRd
  • Belantamab mafodotin
  • Newly diagnosed multiple myeloma
  • RP3D
  • DREAMM 9
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be over 18 years of age inclusive, at the time of signing the .
  • Diagnosis of multiple myeloma with a requirement for treatment as documented per international myeloma working group (IMWG) criteria.
  • Must have at least one aspect of , defined as one of the following:
  • Urine M-protein excretion >=200 mg/24 hours (>=0.2 gram [g]/24 hours), or
  • Serum M-protein concentration >=0.5 grams per deciliter (g/dL) (>=5.0 gram per liter [g/L]), or
  • Serum free light chain (FLC) assay: involved FLC level >=10 milligrams per deciliter (mg/dL) (>=100 milligram per liter [mg/L]) and an abnormal serum free light chain ratio (\<0.26 or >1.65).
  • Not a candidate for high-dose chemotherapy with stem cell transplant (ASCT) due to presence of significant comorbid condition(s), such as cardiac, pulmonary or other major organ dysfunction that are likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation, as judged by the investigator.
  • (ECOG) status of 0-2
  • Adequate organ system functions as defined by the laboratory assessments listed as following: (ANC) >=1.5 x 10\^9/L; >=8.0 g/dL; >=75 x 10\^9/L; Total \<=1.5 x (ULN); (Isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%); (ALT) \<=2.5 x ULN; >=30 mL/minute/1.73 meter\^2; Urine Dipstick for protein OR Albumin/creatinine ratio (from spot urine)- Negative/trace (if >=1 plus only eligible if confirmed \<=500 mg/gram (56 mg/millimoles [mmol]) by albumin/creatinine ratio (spot urine from first void); (LVEF) by echocardiogram (ECHO) of >=35% participants with low LVEF (per institutional standards), consider referring to cardiology per local standards of care.
  • Sex and /Barrier Requirements (Female):
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
  • Is NOT a woman of (WOCBP) or Due to lenalidomide being a thalidomide analogue with risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, and bortezomib having the potential to cause fetal harm, WOCBP participants will be eligible if they commit to either: abstain continuously from heterosexual sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR to use birth control as follows: Two methods of reliable birth control (one method that is highly effective and one additional effective (barrier) method), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use one method of reliable birth control that is highly effective for a further 3 months following discontinuation of belantamab mafodotin, or a further 6 months following discontinuation of bortezomib, whichever is longer. WOCBP must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during treatment, during dose interruptions and for 28-days following the last dose of lenalidomide, 4 months following discontinuation of belantamab mafodotin treatment or 7-months following the last dose of bortezomib, whichever is longer. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing the start of lenalidomide therapy.

The participant should not receive lenalidomide until the investigator has verified that the results of these pregnancy tests are negative. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

  • Sex and Contraception/Barrier Requirements (Male):
  • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Male participants are eligible to participate if they agree to the following from the time of first dose of study treatment until 28-days after the last dose of lenalidomide, 4-months after the last dose of bortezomib, or 6 months after the last dose of belantamab mafodotin, whichever is longer, to allow for clearance of any altered sperm: Refrain from donating sperm - Plus either: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP. Male participants should also use a condom when having sexual intercourse with pregnant females.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Smoldering multiple myeloma (SMM).
  • Prior systemic therapy for multiple myeloma, or SMM. NOTE: An emergency course of (defined as no greater than 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. NOTE: Focal palliative radiation is permitted prior to enrollment, provided that it occurred at least 2 weeks prior to the first dose of study drug, that the participant has recovered from radiation-related toxicities, and that the participant did not require corticosteroids for radiation-induced adverse events.
  • Participant is eligible for high dose chemotherapy with , as determined by a frailty score of 0 as assessed by the IMWG frailty index.
  • Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute (NCI)- (CTCAE) Version 5.
  • Major surgery within 4 weeks prior to the first dose of study drug.
  • Presence of active renal condition (infection, requirement for dialysis or any other significant condition that could affect participant's safety). Participants with isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they fulfil criteria.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining or compliance to the study procedures.
  • Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not explained by reversible coagulopathy.
  • Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the Investigator's assessment).
  • Participants with previous or concurrent other than multiple myeloma are excluded. Exceptions are surgically treated cervical carcinoma in situ, or any other malignancy that has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. Note: Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction.
  • Evidence of cardiovascular risk including any of following: Evidence of current untreated arrhythmias, including clinically significant (ECG) abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.; Class III or IV heart failure as defined by the (NYHA) functional classification system; Uncontrolled hypertension.
  • Active infection requiring treatment.
  • Known (HIV) infection.
  • Presence of surface antigen (HBsAg), or hepatitis B core antibody (HBcAb), at Screening or within 3 months prior to first dose of study treatment.
  • Positive antibody test result.
  • Current corneal epithelial disease except for mild punctate keratopathy. Note: Participants with mild punctate keratopathy are allowed.
  • Intolerance or to anti-viral prophylaxis.
  • Unable to tolerate antithrombotic prophylaxis.
  • AL amyloidosis (light chain amyloidosis), active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS) syndrome or active plasma cell leukemia at the time of screening.
  • Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma.
  • Known immediate or delayed reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Use of an drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd

    Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd

    Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd

    Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd

    Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd

    Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd

    Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd

    Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd

    Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd

    Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd

    Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Selected doses of belantamab mafodotin will be administered as intravenous infusion.

  • Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.

  • Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.

  • Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin

    Criteria for DLT included hematologic indicators including Grade(G) 3-5 febrile neutropenia, G4 neutropenia \>7 days, G3 or greater thrombocytopenia accompanied by clinically significant bleeding; non-hematologic criteria, including Any G3/4 non-hematologic toxicity, G5 non hematologic toxicity, G3 or greater corneal toxicity; Liver toxicity meeting prespecified GSK liver stopping criteria. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: Up to 63 days

  2. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 284 weeks

Secondary outcomes

  1. Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd

    Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).

    Time frame: Up to 168 days

  2. Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd

    Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).

    Time frame: Up to 168 days

  3. Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd

    Cumulative Dose is sum of the actual dose administered during each infusion for a participant.

    Time frame: Up to 84 days

  4. Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Time frame: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  5. Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  6. Time to Reach Cmax (Tmax) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  7. Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. C-trough were measured prior to the next dose for each cycle.

    Time frame: Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49

  8. Observed Plasma Concentration at the End of Infusion (C-EOI) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)

  9. Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive Tlast was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  10. Clearance of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  11. Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  12. Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin

    Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  13. AUC (0 - 504 Hour) of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

    Time frame: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)

  14. Cmax of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Time frame: D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)

  15. Time to Reach Cmax (Tmax) of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)

  16. Observed Plasma C-EOI of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Time frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)

  17. Tlast of Cys-mcMMAF

    Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

    Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)

  18. Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

    Time frame: Up to approximately 234 weeks

  19. Titers of ADAs Against Belantamab Mafodotin

    Serum Samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

    Time frame: Up to approximately 234 weeks

  20. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 hour (h); PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to approximately 284 weeks

  21. Complete Response Rate (CRR)

    CRR is defined as the percentage of participants with a confirmed complete response (CR) or better (i.e. CR and stringent complete response \[sCR\]), according to the IMWG Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 284 weeks

  22. Percentage of Participants With Confirmed VGPR or Better

    VGPR or better (i.e. VGPR, CR, sCR) is defined as - VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h , CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 284 weeks

07

Results

Posted Nov 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Started1212121513192510
Safety population1212121413182410
Dlt evaluable population08108812137
Pharmacokinetic population1212121313182410
Intent-to-treat population1212121513192510
Completed664579135
Not completed66810610125
Withdrew: Physician decision11012030
Withdrew: Withdrawal by subject40242120
Withdrew: Ongoing at the time of analysis03641765
Withdrew: Participants not treated00010110
Withdrew: Subject reached protocol-defined stopping criteria12001100

Outcome measures

SecondaryLenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd

Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).

Time frame:
Up to 168 days
Reported as:
Mean · Percentage of dose
Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd
Percentage of doseCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd74.45 ± 25.39988.79 ± 30.26777.68 ± 24.41486.44 ± 17.12783.72 ± 18.67972.72 ± 29.63579.20 ± 33.75486.02 ± 55.523
SecondaryBortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd

Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).

Time frame:
Up to 168 days
Reported as:
Mean · Percentage of dose
Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd
Percentage of doseCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd59.39 ± 23.39273.26 ± 16.16172.26 ± 19.32078.03 ± 19.12375.00 ± 22.14970.55 ± 16.25872.04 ± 20.99866.27 ± 17.576
SecondaryCumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd

Cumulative Dose is sum of the actual dose administered during each infusion for a participant.

Time frame:
Up to 84 days
Reported as:
Mean · mg
Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd
mgCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd5.03 ± 1.1882.68 ± 0.4043.80 ± 0.8082.67 ± 0.9963.98 ± 1.2712.18 ± 0.5362.91 ± 0.6721.00 ± 0.017
SecondaryArea Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

Time frame:
Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Reported as:
Geometric mean · ug*h/mL
Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin
ug*h/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin2627 ± 22.41861 ± 21.32556 ± 19.51410 ± 20.21870 ± 28.82385 ± 21.72960 ± 24.71620 ± 28.6
SecondaryMaximum Plasma Concentration (Cmax) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Geometric mean · ug/mL
Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin
ug/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin29.7 ± 21.922.5 ± 16.630.5 ± 16.616.2 ± 23.220.8 ± 19.628.0 ± 15.434.7 ± 20.019.4 ± 24.6
SecondaryTime to Reach Cmax (Tmax) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Median · Hours
Time to Reach Cmax (Tmax) of Belantamab Mafodotin
HoursCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Time to Reach Cmax (Tmax) of Belantamab Mafodotin0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)
SecondaryTrough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. C-trough were measured prior to the next dose for each cycle.

Time frame:
Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49
Reported as:
Geometric mean · ug/mL
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin
ug/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin1.22 ± 38.60.806 ± 46.71.18 ± 33.00.646 ± 42.70.892 ± 47.71.24 ± 42.71.48 ± 40.70.807 ± 47.0
SecondaryObserved Plasma Concentration at the End of Infusion (C-EOI) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
Reported as:
Mean · ug/mL
Observed Plasma Concentration at the End of Infusion (C-EOI) of Belantamab Mafodotin
ug/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
CYCLE 1 DAY 128.925 ± 8.402420.800 ± 4.149228.600 ± 8.773022.125 ± 11.563021.138 ± 4.211632.778 ± 9.522338.117 ± 10.635821.060 ± 6.6650
CYCLE 2 DAY 131.050 ± 6.3877——18.127 ± 4.958624.845 ± 7.590029.700 (NA to NA)——
CYCLE 3 DAY 135.980 ± 10.946121.670 ± 4.882429.100 ± 7.148017.411 ± 5.961023.404 ± 6.105528.382 ± 39.906326.900 ± 1.9799—
CYCLE 4 DAY 133.500 ± 6.3640————21.873 ± 9.205927.093 ± 11.3974—
CYCLE 5 DAY 128.400 ± 8.485930.780 ± 9.747733.886 ± 6.7783——25.450 ± 2.899116.000 (NA to NA)20.467 ± 4.2661
CYCLE 6 DAY 1——22.300 (NA to NA)——20.900 ± 6.047033.875 ± 4.8610—
CYCLE 7 DAY 133.700 (NA to NA)21.567 ± 12.4997——20.050 ± 7.990319.786 ± 3.706026.311 ± 5.861017.400 (NA to NA)
CYCLE 8 DAY 1—15.800 (NA to NA)—20.000 (NA to NA)————
CYCLE 9 DAY 1—18.100 (NA to NA)12.700 (NA to NA)15.600 ± 3.394130.000 (NA to NA)17.800 ± 2.642929.460 ± 5.583327.788 ± 9.1431
CYCLE 10 DAY 122.250 ± 4.4548—30.350 ± 5.3033—16.250 ± 0.353621.071 ± 3.921230.180 ± 10.2683—
CYCLE 11 DAY 1—22.000 (NA to NA)20.100 ± 8.3439—19.300 ± 0.0000—24.400 (NA to NA)—
CYCLE 12 DAY 1——19.300 (NA to NA)21.300 (NA to NA)—19.867 ± 4.6004—24.617 ± 7.9248
CYCLE 13 DAY 1—38.000 (NA to NA)——16.500 (NA to NA)19.000 (NA to NA)28.400 (NA to NA)—
CYCLE 14 DAY 127.100 (NA to NA)—19.100 ± 8.3439——22.500 (NA to NA)——
CYCLE 15 DAY 131.467 ± 3.027122.200 ± 11.455145.300 (NA to NA)——15.567 ± 4.517043.867 ± 12.1150—
CYCLE 16 DAY 120.900 (NA to NA)————25.500 ± 4.686114.940 ± 2.941615.700 (NA to NA)
CYCLE 17 DAY 113.300 (NA to NA)—44.700 (NA to NA)18.800 (NA to NA)————
CYCLE 18 DAY 1——18.900 (NA to NA)27.600 (NA to NA)—19.700 (NA to NA)—19.467 ± 2.9023
CYCLE 19 DAY 1—32.200 (NA to NA)———21.500 (NA to NA)——
CYCLE 20 DAY 1———————16.500 (NA to NA)
CYCLE 21 DAY 1———25.800 (NA to NA)————
CYCLE 22 DAY 1—15.800 (NA to NA)——————
CYCLE 24 DAY 1——19.800 (NA to NA)—————
CYCLE 25 DAY 1——20.200 (NA to NA)———26.500 (NA to NA)—
CYCLE 26 DAY 1—35.400 (NA to NA)——————
CYCLE 27 DAY 1——25.100 (NA to NA)18.700 (NA to NA)————
SecondaryTime of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive Tlast was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Reported as:
Median · Hours
Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin
HoursCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin505 (502 to 526)501 (482 to 506)501 (477 to 505)505 (480 to 507)505 (502 to 508)501 (492 to 504)499 (478 to 503)499 (434 to 526)
SecondaryClearance of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Geometric mean · Liter (L) /Days
Clearance of Belantamab Mafodotin
Liter (L) /DaysCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Clearance of Belantamab Mafodotin1.1 ± 26.41.1 ± 40.61 ± 21.10.92 ± 27.90.97 ± 37.30.84 ± 22.60.89 ± 36.10.89 ± 26.8
SecondaryVolume of Distribution at Steady State (Vss) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Geometric mean · Liter
Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin
LiterCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin13 ± 17.512 ± 18.912 ± 18.59.9 ± 32.511 ± 20.311 ± 29.59.5 ± 20.39.1 ± 20.2
SecondaryApparent Terminal Half Life (t1/2) of Belantamab Mafodotin

Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Geometric mean · Days
Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin
DaysCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin14 ± 23.714 ± 23.914 ± 19.112 ± 37.113 ± 32.614 ± 38.412 ± 20.711 ± 17.8
SecondaryAUC (0 - 504 Hour) of Cys-mcMMAF

Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.

Time frame:
Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Reported as:
Geometric mean · ng*h/mL
AUC (0 - 504 Hour) of Cys-mcMMAF
ng*h/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
AUC (0 - 504 Hour) of Cys-mcMMAF3.66 ± 48.23.28 ± 114.93.31 ± 65.51.9 ± 33.12.76 ± 27.13.68 ± 614.63 ± 54.12.01 ± 22.5
SecondaryCmax of Cys-mcMMAF

Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

Time frame:
D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)
Reported as:
Geometric mean · ng/mL
Cmax of Cys-mcMMAF
ng/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Cmax of Cys-mcMMAF0.7 ± 37.70.66 ± 111.40.67 ± 55.20.38 ± 50.10.57 ± 50.10.68 ± 80.70.91 ± 56.60.4 ± 31.9
SecondaryTime to Reach Cmax (Tmax) of Cys-mcMMAF

Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Reported as:
Median · Hours
Time to Reach Cmax (Tmax) of Cys-mcMMAF
HoursCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Time to Reach Cmax (Tmax) of Cys-mcMMAF24 (0.5 to 72)24 (24 to 24)24 (24 to 24)24 (24 to 24)24 (24 to 24)24 (24 to 72)24 (24 to 24)24 (24 to 24)
SecondaryObserved Plasma C-EOI of Cys-mcMMAF

Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

Time frame:
End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
Reported as:
Mean · ng/mL
Observed Plasma C-EOI of Cys-mcMMAF
ng/mLCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
CYCLE 1 DAY 10.251 ± 0.12990.260 ± 0.08460.351 ± 0.18930.184 ± 0.13990.289 ± 0.17510.272 ± 0.11340.349 ± 0.17920.568 ± 1.4345
CYCLE 2 DAY 10.263 ± 0.1018——0.142 ± 0.03390.270 ± 0.14680.256 (NA to NA)——
CYCLE 3 DAY 10.353 ± 0.12460.304 ± 0.23160.338 ± 0.12810.129 ± 0.02410.189 ± 0.11430.095 ± 0.13440.119 ± 0.0350—
CYCLE 4 DAY 10.438 ± 0.1492————0.153 ± 0.05680.226 ± 0.1413—
CYCLE 5 DAY 10.225 ± 0.02840.245 ± 0.12540.251 ± 0.0912——0.153 ± 0.00420.248 (NA to NA)0.127 ± 0.0464
CYCLE 6 DAY 1——0.619 (NA to NA)——0.140 ± 0.03910.171 ± 0.0537—
CYCLE 7 DAY 10.200 (NA to NA)0.074 ± 0.0699——0.119 ± 0.04820.138 ± 0.04370.193 ± 0.07290.090 (NA to NA)
CYCLE 8 DAY 1—0.155 (NA to NA)—0.192 (NA to NA)————
CYCLE 9 DAY 1—0.141 (NA to NA)0.457 (NA to NA)0.276 ± 0.22980.180 (NA to NA)0.118 ± 0.05710.228 ± 0.09540.137 ± 0.0620
CYCLE 10 DAY 10.178 ± 0.0976—0.168 ± 0.0495—0.137 ± 0.05550.125 ± 0.04640.124 ± 0.0322—
CYCLE 11 DAY 1—0.195 (NA to NA)0.420 ± 0.4835—0.272 ± 0.1874—0.163 (NA to NA)—
CYCLE 12 DAY 1——0.153 (NA to NA)0.114 (NA to NA)—0.154 ± 0.0679—0.090 ± 0.0632
CYCLE 13 DAY 1—0.306 (NA to NA)——0.164 (NA to NA)0.104 (NA to NA)0.105 (NA to NA)—
CYCLE 14 DAY 10.325 (NA to NA)—0.124 ± 0.0364——0.105 (NA to NA)——
CYCLE 15 DAY 10.242 ± 0.14080.137 ± 0.02330.117 (NA to NA)——0.082 ± 0.02260.219 ± 0.0900—
CYCLE 16 DAY 10.507 (NA to NA)————0.105 ± 0.01620.097 ± 0.02630.063 (NA to NA)
CYCLE 17 DAY 10.309 (NA to NA)—0.384 (NA to NA)0.188 (NA to NA)————
CYCLE 18 DAY 1——0.192 (NA to NA)0.188 (NA to NA)—0.112 (NA to NA)—0.088 ± 0.0253
CYCLE 19 DAY 1—0.120 (NA to NA)———0.071 (NA to NA)——
CYCLE 20 DAY 1———————0.064 (NA to NA)
CYCLE 21 DAY 1———0.150 (NA to NA)————
CYCLE 22 DAY 1—0.123 (NA to NA)——————
CYCLE 24 DAY 1——0.192 (NA to NA)—————
CYCLE 25 DAY 1——0.128 (NA to NA)———0.242 (NA to NA)—
CYCLE 26 DAY 1—0.238 (NA to NA)——————
CYCLE 27 DAY 1——0.095 (NA to NA)0.273 (NA to NA)————
SecondaryTlast of Cys-mcMMAF

Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.

Time frame:
Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)
Reported as:
Median · Hours
Tlast of Cys-mcMMAF
HoursCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Tlast of Cys-mcMMAF168 (68 to 241)167 (71.5 to 210)165 (3.02 to 193)165 (67.1 to 236)167 (2 to 237)165 (67.7 to 331)165 (2.22 to 238)165 (67.2 to 190)
SecondaryNumber of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

Time frame:
Up to approximately 234 weeks
Reported as:
Count of participants · Participants
Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
ParticipantsCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin00011010
SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum Samples were collected for the analysis of ADAs of anti-belantamab mafodotin.

Time frame:
Up to approximately 234 weeks
Reported as:
Median · Titers
Titers of ADAs Against Belantamab Mafodotin
TitersCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Titers of ADAs Against Belantamab Mafodotin———400.0100.0—100.0—
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 hour (h); PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to approximately 284 weeks
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Overall Response Rate (ORR)100 (73.5 to 100.0)92 (61.5 to 99.8)100 (73.5 to 100.0)80 (51.9 to 95.7)92 (64.0 to 99.8)84 (60.4 to 96.6)80 (59.3 to 93.2)100 (69.2 to 100.0)
SecondaryComplete Response Rate (CRR)

CRR is defined as the percentage of participants with a confirmed complete response (CR) or better (i.e. CR and stringent complete response \[sCR\]), according to the IMWG Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 284 weeks
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Complete Response Rate (CRR)75 (42.8 to 94.5)83 (51.6 to 97.9)92 (61.5 to 99.8)67 (38.4 to 88.2)62 (31.6 to 86.1)58 (33.5 to 79.7)48 (27.8 to 68.7)90 (55.5 to 99.7)
SecondaryPercentage of Participants With Confirmed VGPR or Better

VGPR or better (i.e. VGPR, CR, sCR) is defined as - VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h , CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 284 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed VGPR or Better
Percentage of ParticipantsCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Percentage of Participants With Confirmed VGPR or Better92 (61.5 to 99.8)92 (61.5 to 99.8)100 (73.5 to 100.0)73 (44.9 to 92.2)92 (64.0 to 99.8)74 (48.8 to 90.9)68 (46.5 to 85.1)100 (69.2 to 100.0)
PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin

Criteria for DLT included hematologic indicators including Grade(G) 3-5 febrile neutropenia, G4 neutropenia \>7 days, G3 or greater thrombocytopenia accompanied by clinically significant bleeding; non-hematologic criteria, including Any G3/4 non-hematologic toxicity, G5 non hematologic toxicity, G3 or greater corneal toxicity; Liver toxicity meeting prespecified GSK liver stopping criteria. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

Time frame:
Up to 63 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin
ParticipantsCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin0010000
PrimaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 284 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
Number of Participants With Adverse Events (AEs)1212121413182410

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected upto approximately 284 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd2/12 (16.7%)11/12 (91.7%)12/12 (100%)
Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd4/12 (33.3%)10/12 (83.3%)12/12 (100%)
Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd1/12 (8.3%)11/12 (91.7%)12/12 (100%)
Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd0/14 (0%)8/14 (57.1%)14/14 (100%)
Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd2/13 (15.4%)6/13 (46.2%)13/13 (100%)
Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd5/18 (27.8%)13/18 (72.2%)18/18 (100%)
Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd2/24 (8.3%)14/24 (58.3%)23/24 (95.8%)
Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd0/10 (0%)7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
COVID-19 pneumoniaInfections and infestations2/123/125/122/141/132/182/241/10
PneumoniaInfections and infestations4/122/122/120/142/132/182/242/10
BronchitisInfections and infestations0/120/120/120/140/130/180/242/10
Femur fractureInjury, poisoning and procedural complications0/122/120/120/140/130/181/240/10
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/122/121/120/140/131/180/241/10
PyrexiaGeneral disorders2/120/120/121/141/131/180/240/10
Orthostatic hypotensionVascular disorders2/120/120/120/140/130/180/240/10
COVID-19Infections and infestations0/120/121/122/141/130/182/240/10
Lower respiratory tract infectionInfections and infestations0/121/120/122/140/130/181/241/10
Back painMusculoskeletal and connective tissue disorders0/120/121/122/140/130/180/240/10
Most frequent other events
Showing 10 of 483
Most frequent other events
EventCohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd
COVID-19Infections and infestations2/127/1210/123/143/135/185/241/10
Vision blurredEye disorders7/127/126/125/147/132/187/247/10
ConstipationGastrointestinal disorders8/125/125/126/146/131/186/243/10
ThrombocytopeniaBlood and lymphatic system disorders7/128/126/126/147/138/1811/246/10
Neuropathy peripheralNervous system disorders5/125/122/124/148/134/184/242/10
DiarrhoeaGastrointestinal disorders6/127/126/126/148/137/189/245/10
Oedema peripheralGeneral disorders6/124/125/124/146/132/187/246/10
Peripheral sensory neuropathyNervous system disorders2/127/127/123/142/136/185/243/10
InsomniaPsychiatric disorders7/123/121/122/142/135/183/244/10
Dry eyeEye disorders4/123/126/124/144/132/185/244/10

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/RdTotal
Mean71.5 ± 4.7873.1 ± 3.4573.5 ± 2.8471.1 ± 8.3574.5 ± 5.6171.6 ± 9.1476.2 ± 6.1575.3 ± 5.0373.5 ± 6.46
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/RdTotal
Female46685712553
Male866781213565
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/RdCohort 2: Bela 1.4 mg/kg Q6/8W + VRd/RdCohort 3: Bela 1.9 mg/kg Q6/8W + VRd/RdCohort 4: Bela 1.0 mg/kg Q3/4W + VRd/RdCohort 5: Bela 1.4 mg/kg Q3/4W + VRd/RdCohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/RdCohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/RdCohort 8: Bela 1.0 mg/kg Q12W + VRd/RdTotal
American Indian or Alaska Native000000000
Asian2242201013
Native Hawaiian or Other Pacific Islander000000000
Black or African American000100102
White101081211192310103
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

30 sites
  • GSK Investigational Site
    Westwood, Kansas 66205, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792-0001, United States
  • GSK Investigational Site
    Newcastle, New South Wales 2298, Australia
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    London, Ontario N6A 5W9, Canada
  • GSK Investigational Site
    Poitiers, 86021, France
  • GSK Investigational Site
    Dresden, 01307, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Schwerin, 19049, Germany
  • GSK Investigational Site
    Tübingen, 72076, Germany
  • GSK Investigational Site
    Bologna, 40138, Italy
  • GSK Investigational Site
    Meldola FC, 47014, Italy
  • GSK Investigational Site
    Lublin, 20-081, Poland
  • GSK Investigational Site
    Poznan, 61-848, Poland
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 137-701, South Korea
  • GSK Investigational Site
    Badalona, Barcelona 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    PamplonaNavarra, 31008, Spain
  • GSK Investigational Site
    Pozuelo de AlarcOn Madr, 28223, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Southampton, Hampshire SO16 6YD, United Kingdom
  • GSK Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • GSK Investigational Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2025, 65 months.

Results were first posted in Nov 2026, 1 year 5 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 65 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2028, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2019
First posted
Sep 16, 2019
StartActual
Dec 18, 2019
Primary completionActual
Jun 2, 2025
CompletionEst.
Mar 10, 2028was Dec 2026
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Spain, 1 United Kingdom)
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · Southampton, United Kingdom
Show 2 removed
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · Southampton, United Kingdom
Nov 9, 2026
Study completion
Dec 31, 2026→Mar 10, 2028
Nov 9, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of participants with doseParticipants With Dose-limiting toxicitiesToxicities (DLTs) of Belantamab MafodotinTime frame: Treatment cycle 1 to 3 (each cycle of 21 days) → Up to 63 days
  • EditedNumber of participants with adverse eventsParticipants With Adverse Events (AEs) and serious adverse events (SAEs)Time frame: Up to an average of 54 months → Up to approximately 284 weeks
Nov 9, 2026
Documents
Secondary outcomes
8 edited, 2 time frame changed, 12 added, 2 removed, 2 description edited
What changed in the outcomes
  • EditedLenalidomide relative dose intensityRelative Dose Intensity (RDI ) of treatment with belantamab mafodotinAfter Treatment With Belantamab Mafodotin in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 168 days
  • EditedBortezomib RDI of treatment with belantamab mafodotinAfter Treatment With Belantamab Mafodotin in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 168 days
  • EditedCumulative administered doseAdministered Dose of belantamab mafodotin treatmentBelantamab Mafodotin After Treatment in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 84 days
  • EditedMaximum plasma concentrationPlasma Concentration (Cmax) of belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • EditedArea underUnder the concentration time curveConcentration Time Curve From 0 to 504 Hours [AUC (AUC0 - 504 Hours)] of belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
  • EditedAUC (0 - 504 Hour) of cysCys-mcMMAFTime frame: Up to an average of 52 months → Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
  • EditedNumber of participants with positive antiParticipants With Positive Post-baseline Anti-drug antibodiesAntibodies (ADAs) against belantamab mafodotinAgainst Belantamab MafodotinTime frame: Up to an average of 52 months → Up to approximately 234 weeks
  • EditedTitersClearance of ADAs against belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • AddedTime to Reach Cmax (Tmax) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • AddedTrough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab MafodotinTime frame: Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49
  • AddedObserved Plasma Concentration at the End of Infusion (C-EOI) of Belantamab MafodotinTime frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
  • AddedTime of Last Observed Quantifiable Concentration (Tlast) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
  • AddedVolume of Distribution at Steady State (Vss) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • AddedApparent Terminal Half Life (t1/2) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • AddedCmax of Cys-mcMMAFTime frame: D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)
  • AddedTime to Reach Cmax (Tmax) of Cys-mcMMAFTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
  • AddedObserved Plasma C-EOI of Cys-mcMMAFTime frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
  • AddedTlast of Cys-mcMMAFTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)
  • AddedTiters of ADAs Against Belantamab MafodotinTime frame: Up to approximately 234 weeks
  • AddedPercentage of Participants With Confirmed VGPR or BetterTime frame: Up to approximately 284 weeks
  • RemovedCmax of microtubule inhibitor monomethyl auristatin-F with a cysteine linker (cys-mcMMAF)Time frame: Up to an average of 52 months
  • RemovedRate of Very Good Partial Response (VGPR) or betterTime frame: Up to 52 months
  • Time frameOverall Response Rate (ORR)Up to 52 months → Up to approximately 284 weeks
  • Time frameComplete Response Rate (CRR)Up to 52 months → Up to approximately 284 weeks
  • DescriptionComplete Response Rate (CRR): how it is measured was reworded
  • DescriptionOverall Response Rate (ORR): how it is measured was reworded
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (1 Spain, 1 United Kingdom)
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · Southampton, United Kingdom
    Show 2 removed
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · Southampton, United Kingdom
    Study completion Dec 31, 2026→Mar 10, 2028
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of participants with doseParticipants With Dose-limiting toxicitiesToxicities (DLTs) of Belantamab MafodotinTime frame: Treatment cycle 1 to 3 (each cycle of 21 days) → Up to 63 days
    • EditedNumber of participants with adverse eventsParticipants With Adverse Events (AEs) and serious adverse events (SAEs)Time frame: Up to an average of 54 months → Up to approximately 284 weeks
    Secondary outcomes 8 edited, 2 time frame changed, 12 added, 2 removed, 2 description edited
    What changed in the outcomes
    • EditedLenalidomide relative dose intensityRelative Dose Intensity (RDI ) of treatment with belantamab mafodotinAfter Treatment With Belantamab Mafodotin in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 168 days
    • EditedBortezomib RDI of treatment with belantamab mafodotinAfter Treatment With Belantamab Mafodotin in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 168 days
    • EditedCumulative administered doseAdministered Dose of belantamab mafodotin treatmentBelantamab Mafodotin After Treatment in combination withCombination With VRdTime frame: 4 treatment cycles (each cycle of 21 days) → Up to 84 days
    • EditedMaximum plasma concentrationPlasma Concentration (Cmax) of belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • EditedArea underUnder the concentration time curveConcentration Time Curve From 0 to 504 Hours [AUC (AUC0 - 504 Hours)] of belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
    • EditedAUC (0 - 504 Hour) of cysCys-mcMMAFTime frame: Up to an average of 52 months → Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
    • EditedNumber of participants with positive antiParticipants With Positive Post-baseline Anti-drug antibodiesAntibodies (ADAs) against belantamab mafodotinAgainst Belantamab MafodotinTime frame: Up to an average of 52 months → Up to approximately 234 weeks
    • EditedTitersClearance of ADAs against belantamab mafodotinBelantamab MafodotinTime frame: Up to an average of 52 months → Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • AddedTime to Reach Cmax (Tmax) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • AddedTrough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab MafodotinTime frame: Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49
    • AddedObserved Plasma Concentration at the End of Infusion (C-EOI) of Belantamab MafodotinTime frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
    • AddedTime of Last Observed Quantifiable Concentration (Tlast) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
    • AddedVolume of Distribution at Steady State (Vss) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • AddedApparent Terminal Half Life (t1/2) of Belantamab MafodotinTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • AddedCmax of Cys-mcMMAFTime frame: D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)
    • AddedTime to Reach Cmax (Tmax) of Cys-mcMMAFTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
    • AddedObserved Plasma C-EOI of Cys-mcMMAFTime frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
    • AddedTlast of Cys-mcMMAFTime frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)
    • AddedTiters of ADAs Against Belantamab MafodotinTime frame: Up to approximately 234 weeks
    • AddedPercentage of Participants With Confirmed VGPR or BetterTime frame: Up to approximately 284 weeks
    • RemovedCmax of microtubule inhibitor monomethyl auristatin-F with a cysteine linker (cys-mcMMAF)Time frame: Up to an average of 52 months
    • RemovedRate of Very Good Partial Response (VGPR) or betterTime frame: Up to 52 months
    • Time frameOverall Response Rate (ORR)Up to 52 months → Up to approximately 284 weeks
    • Time frameComplete Response Rate (CRR)Up to 52 months → Up to approximately 284 weeks
    • DescriptionComplete Response Rate (CRR): how it is measured was reworded
    • DescriptionOverall Response Rate (ORR): how it is measured was reworded
    + 4 other changes: identifiers, verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04091126
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Dec 18, 2019
Primary completion
Jun 2, 2025
Completion
Mar 10, 2028 (estimated)
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion